PMID- 8950769
OWN - NLM
STAT- MEDLINE
DCOM- 19970324
LR  - 20061115
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 76
IP  - 5
DP  - 1996 Nov
TI  - Correlation between oxidized low density lipoproteins and von Willebrand factor 
      in chronic renal failure.
PG  - 663-9
AB  - An ELISA specific for a wide spectrum of oxidized apo B-100 in OxLDL was 
      developed and applied to blood samples from 27 control subjects, 20 mild chronic 
      renal failure (MCRF) patients, 21 severe chronic renal failure patients on 
      conservative treatment (SCRF) and 56 severe chronic renal failure patients on 
      maintenance hemodialysis (HEMO). Mean levels of OxLDL were 0.59 mg/dl in controls 
      (95% CI, 0.52-0.66 mg/dl), and were 2.7-fold (p < 0.01), 3.1-fold (p < 0.001) and 
      5.4-fold (p < 0.001) higher in MCRF, SCRF and HEMO patients, respectively. Levels 
      of von Willebrand factor, a marker of endothelial injury, were 100 percent in 
      controls (95% CI, 90-110 percent), and were 1.5-fold (p = NS), 1.6-fold (p < 
      0.01) and 2.1-fold (p < 0.001) higher in MCRF, SCRF and HEMO patients, 
      respectively. Multiple regression analysis revealed that the extent of renal 
      failure (F = 14; p = 0.0004) accounted for a significant fraction of the 
      variation in OxLDL levels, also after exclusion of patients with evidence of 
      ischemic atherosclerotic disease (F = 21; p = 0.0001). After adjustment for the 
      extent of renal failure, hemodialysis (F = 5.6; p = 0.021) and LDL cholesterol 
      levels (F = 7.1, p = 0.0095) contributed significantly to the variation in OxLDL 
      levels. Whereas the extent of renal failure contributed only marginally to the 
      individual variations in vWF levels (F = 4.1; p = 0.048), these levels correlated 
      significantly with plasma levels of OxLDL (F = 26; p = 0.0001). In conclusion, 
      OxLDL increase progressively during the development of renal failure suggesting 
      that the oxidation of LDL may be associated with endothelial injury and 
      atherogenesis in these patients.
FAU - Holvoet, P
AU  - Holvoet P
AD  - Center for Molecular and Vascular Biology, University of Leuven, Belgium.
FAU - Donck, J
AU  - Donck J
FAU - Landeloos, M
AU  - Landeloos M
FAU - Brouwers, E
AU  - Brouwers E
FAU - Luijtens, K
AU  - Luijtens K
FAU - Arnout, J
AU  - Arnout J
FAU - Lesaffre, E
AU  - Lesaffre E
FAU - Vanrenterghem, Y
AU  - Vanrenterghem Y
FAU - Collen, D
AU  - Collen D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Apolipoprotein B-100)
RN  - 0 (Apolipoproteins B)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (oxidized low density lipoprotein)
RN  - 0 (von Willebrand Factor)
SB  - IM
MH  - Aged
MH  - Apolipoprotein B-100
MH  - Apolipoproteins B/*analysis/chemistry
MH  - Arteriosclerosis/*epidemiology
MH  - Cardiovascular Diseases/epidemiology
MH  - Cholesterol, LDL/blood
MH  - Comorbidity
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Hypertension/complications
MH  - Kidney Failure, Chronic/*blood/epidemiology/therapy
MH  - Lipoproteins, LDL/*blood
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Renal Dialysis
MH  - Risk Factors
MH  - von Willebrand Factor/*analysis
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1996 Nov;76(5):663-9.